From the Agenda

Boosting Production Titers by SPOT

2017-11-24 15:00

Dr. Louis Boon

Chief Scientific Officer

Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. In 2003, he was one of the founders of Bioceros BV were he currently hold a position of CSO.
Bioceros generates production cell lines for the industry and used its proprietary CHO platform to generate a portfolio of cell lines producing biosimilar monoclonal antibodies. Since the acquisition of Bioceros by EPIRUS in 2015, he extended this expertise and developed a complete process toolbox to fit biosimilar CQAs. After the acquisition of Epirus NL by the Polpharma Biologics group in June 2016, he has continued to work on biosimilar development and developed the SPOT technology to improve cell line productivity. 

Next to biosimilars, Dr. Boon is also responsible for the discovery and development of innovative new molecular antibody entities, which now within the Polpharma Biologics group can be extended to GMP production and clinical testing.  In addition, before he founded Bioceros, he held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP Preclinical for PanGenetics BV and Tanox. Dr. Boon is author of over 260 papers in international scientific journals in the field of medical biotechnology.